Trial Profile
A Phase 1/2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Lisocabtagene-maraleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRANSCEND PEDALL
- Sponsors Celgene Corporation
- 19 Apr 2024 Status changed from recruiting to completed.
- 03 Apr 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 25 Mar 2024 This trial has been discontinued in Germany, according to European Clinical Trials Database record.